119 related articles for article (PubMed ID: 20669178)
21. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
Warzocha K; Kraj M; Pogłód R; Kwaśniak B
Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
[No Abstract] [Full Text] [Related]
22. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Delforge M; Terpos E; Richardson PG; Shpilberg O; Khuageva NK; Schlag R; Dimopoulos MA; Kropff M; Spicka I; Petrucci MT; Samoilova OS; Mateos MV; Magen-Nativ H; Goldschmidt H; Esseltine DL; Ricci DS; Liu K; Deraedt W; Cakana A; van de Velde H; San Miguel JF
Eur J Haematol; 2011 May; 86(5):372-84. PubMed ID: 21366694
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
[TBL] [Abstract][Full Text] [Related]
24. [Complete double remission and prolonged survival of a patient diagnosed with plasma cell leukemia].
Sureda A; Pérez de Oteyza J; García Laraña J; Odriozola J
Sangre (Barc); 1989 Jun; 34(3):244. PubMed ID: 2762986
[No Abstract] [Full Text] [Related]
25. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
[TBL] [Abstract][Full Text] [Related]
26. [Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy].
Shindo T; Yumoto Y; Yoshida M; Okuda T
Rinsho Ketsueki; 2002 Feb; 43(2):107-11. PubMed ID: 11925872
[TBL] [Abstract][Full Text] [Related]
27. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
[TBL] [Abstract][Full Text] [Related]
28. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.
Grassinger J; Südhoff T; Andreesen R; Hennemann B
Ann Hematol; 2006 Feb; 85(2):132-3. PubMed ID: 16311736
[No Abstract] [Full Text] [Related]
29. [Plasma cell leukemia: our experience in 4 cases].
Manso F; Bello JL; Feliu J; García de Bustos J; Losada G; Quevedo E
Rev Clin Esp; 1991 Nov; 189(7):328-30. PubMed ID: 1767090
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
[TBL] [Abstract][Full Text] [Related]
31. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
32. Plasma cell leukemia--report on two cases.
Singh VP; Sundar S; Kumar K; Shukla J; Dube B
J Assoc Physicians India; 1994 Oct; 42(10):824-5. PubMed ID: 7876056
[No Abstract] [Full Text] [Related]
33. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Berenson JR; Yellin O; Woytowitz D; Flam MS; Cartmell A; Patel R; Duvivier H; Nassir Y; Eades B; Abaya CD; Hilger J; Swift RA
Eur J Haematol; 2009 Jun; 82(6):433-9. PubMed ID: 19226361
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
San-Miguel J; Bladé J; Shpilberg O; Grosicki S; Maloisel F; Min CK; Polo Zarzuela M; Robak T; Prasad SV; Tee Goh Y; Laubach J; Spencer A; Mateos MV; Palumbo A; Puchalski T; Reddy M; Uhlar C; Qin X; van de Velde H; Xie H; Orlowski RZ
Blood; 2014 Jun; 123(26):4136-42. PubMed ID: 24833354
[TBL] [Abstract][Full Text] [Related]
35. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
36. [Case of plasmacytic leukemia with complete remission and 1-year survival after a combined 5-drug sequence therapy].
Anisimowicz J; Mizan K
Pol Tyg Lek; 1984 Sep; 39(36):1209-10. PubMed ID: 6504747
[No Abstract] [Full Text] [Related]
37. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
Lee JY; Lim SH; Kim SJ; Lee GY; Lee JE; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
Amyloid; 2014 Dec; 21(4):261-6. PubMed ID: 25248716
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
40. Successful bortezomib-based treatment in POEMS syndrome.
Tang X; Shi X; Sun A; Qiu H; Gu B; Zhou H; Xue S; Liu Y; Ruan C; Wu D
Eur J Haematol; 2009 Dec; 83(6):609-10. PubMed ID: 19674063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
